Key Takeaway: Martin Hosking, Ph.D., is the Head of Research at Fate Therapeutics, focusing on iPSC-derived immune cell therapies for cancer and autoimmune diseases. With over 20 years of experience, he has contributed significantly to the field through research and patents. He holds both a Ph.D. and B.S. from UC Irvine.
Price reaction · baseline $0.9702 (2025-03-04T15:13:00.000Z) · hit during market hours · 2 other FATE headline(s) in the window, move may be shared
day 0 close · peak
-2.1%
Market Sentiment Analysis
POSITIVE FACTORS
Dr. Hosking has extensive experience in research and leadership.
He is advancing innovative therapies for cancer and autoimmune diseases.
His work includes numerous studies and patents in immune cell responses.
Full Press Release Details
Martin Hosking is Head of Research at Fate Therapeutics and is responsible for overseeing and advancing the development of iPSC-derived immune cell therapies to clinical evaluation for patients with cancer and autoimmune diseases. With more than two decades of research and leadership experience spread across academia and biotechnology, Dr. Hosking has co-authored numerous studies and patents related to the generation, regulation, and maintenance of immune cell responses to cancer and viruses. Dr. Hosking received both his Ph.D. and B.S. from the Department of Molecular Biology and Biochemistry, Biological Sciences at the University of California, Irvine.
Frequently Asked Questions
What is Martin Hosking's role at Fate Therapeutics?
He is the Head of Research, overseeing iPSC-derived immune cell therapies.
What is the focus of Dr. Hosking's research?
His research focuses on therapies for cancer and autoimmune diseases.
Where did Martin Hosking earn his degrees?
He received his Ph.D. and B.S. from the University of California, Irvine.
How many years of experience does Dr. Hosking have?
He has over two decades of research and leadership experience.